Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Descartes-11 in Relapsed/Refractory Multiple Myeloma
NCT03994705Phase 1Terminated
- Sponsor
- Cartesian Therapeutics
- Start
- Aug 2019
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Descartes-11 in multiple myeloma (MM) (6 arms), sponsored by Cartesian Therapeutics. Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 21 days. Started Aug 2019; status: terminated.
02
Drugs
Descartes-11
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03994705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994705.